Archive | January 2020
You are browsing the site archives by date.
Flu vaccination to cure cancer?
Photo by CDC on Unsplash A recent study in the journal PNAS has demonstrated that influence vaccination in cancer patients makes them more susceptible to immune checkpoint inhibitors like Keytruda. In addition, vaccination was able to change the tumor microenvironment from an immune-suppressive state to an inflammatory state. What the authors have described here is a dual-advantage approach. […]
AstraZeneca, Merck’s pancreatic cancer drug cleared by FDA
Pancreatic cancer is difficult to treat. While precision has helped make significant strides in improved overall survival in other cancers, pancreatic cancer has been left behind. This week, Astra Zeneca and Merck’s Lynparza, a drug that targets the BRCA mutation, was cleared by the FDA. The BRCA mutation is found in breast and ovarian cancers. A […]
Low grade gliomas : Need for new therapeutic approaches
Gliomas are the most common type of brain tumors. Based on aggressiveness, they are classified as grades I- IV, with Grade IV being the most aggressive. Grade IV gliomas, also called Glioblastoma Multiforme (GBM), is one of the most aggressive cancers with a median survival of 12-16 months after surgery, chemotherapy and Radiation therapy. Understandably, […]
Major events in Immunology/ Oncology – 2019
As the year winds down and the next decade is on the horizon, I thought it would be nice to take a trip down memory lane and re-visit some of the major news in the Immunology/ Oncology biotech space in 2019. 1) Celgene releases promising CAR-T data Celgene released promising data for its CAR-T cell therapy […]
Innately Immune 